NDAORALTABLET
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
LYMEPAK (doxycycline hyclate) by Molecular Devices is tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. Approved for gonorrhea, chlamydia, syphilis and 1 more indications. First approved in 2018.
Drug data last refreshed 20h ago
Mechanism of Action
Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral…
Worked on LYMEPAK at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.